WP
LENZ

Woodline Partners’s LENZ Therapeutics LENZ Stock Holding History

Woodline Partners’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$915K Hold
100,000
– – ﹤0.01% 896
2025
Q4 		$1.6M Buy
+100,000
New +$2.91M 0.01% 799
2022
Q3 		– Sell
-42,862
Closed -$825K – 836
2022
Q2 		$825K Hold
42,862
– – 0.01% 533
2022
Q1 		$1.53M Hold
42,862
– – 0.02% 413
2021
Q4 		$3.73M Hold
42,862
– – 0.05% 325
2021
Q3 		$4.92M Sell
42,862
-1,384
-3% -$205K 0.08% 254
2021
Q2 		$9.52M Buy
+44,246
New +$7.71M 0.18% 139

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Woodline Partners's LENZ Position: Q1 2026 in Review

Woodline Partners held its LENZ Therapeutics (LENZ) position steady in Q1 2026 at 100,000 shares worth $915K. The position accounts for ﹤0.01% of the portfolio, ranked #896.

Woodline Partners first reported a position in LENZ in Q2 2021 and has held it in 7 quarters since. The position peaked at $9.52M in Q2 2021. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Woodline Partners held 100,000 shares of LENZ Therapeutics worth $915K as of Q1 2026.
  • Woodline Partners left its LENZ Therapeutics share count unchanged in Q1 2026.
  • LENZ Therapeutics made up ﹤0.01% of Woodline Partners's portfolio in Q1 2026, its #896 holding.
  • Woodline Partners first reported a position in LENZ Therapeutics in Q2 2021 and has held it in 7 quarters since.
  • Woodline Partners's LENZ Therapeutics position peaked at $9.52M in Q2 2021.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.